Abstract
The reactions of 5-azido-3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde (azidopyrazole) with several classes of organophosphorus reagents: phosphonium ylides, Wittig-Horner reagents, dialkylphosphonates, trialkylphosphites, tris(dialkylamino)phosphanes, triphenylstibane, triphenylarsane, and Lawesson’s reagent are reported. Structural reasoning for the new products was based on compatible analytical and spectral data. The cytotoxic activity of most of the new products was evaluated against human breast carcinoma cell line (MCF7) and human hepatocellular carcinoma cell line(HepG2). Certain tested compounds showed promising results.
1 Introduction
The easily prepared pyrazole ring is an interesting template for combinatorial [1, 2] and medicinal chemistry [3, 4] as well as a prominent structural motif found in numerous pharmaceutically active compounds [5]. Moreover, the pyrazole derivatives are known to have pharmacological, antimicrobial, antifungal [6], and antitumor [7] activities. In view of this and in continuation of our work in organophosphorus chemistry [8–12], it was of considerable interest to investigate the behavior of azidopyrazole 1 toward phosphonium ylides 2a–c, Wittig-Horner reagents 3a,b, diethylphosphonate 4, trialkylphosphites 5a,b, tris(dialkylamino)phosphanes 5c,d, triphenylstibane 6a, triphenylarsane 6b, and Lawesson’s reagent (LR) 7 (Fig. 1).

Azidopyrazole 1, organophosphorus reagents 2–6 and LR 7. The purpose of this study was to determine the preferential site of attack by these reagents and synthesize new P-containing pyrazole derivatives with anticipated biological activities.
2 Results and discussion
2.1 Chemistry
When azidopyrazole 1 was treated with two molar equivalents of (cyanomethylene)triphenylphosphorane (2a) in dry THF at ambient temperature for 1 h, the triphenyl phosphoranylidenesuccinonitrile 8a was obtained (85% yield). Triphenylphosphane oxide (TPPO) was also isolated and identified (Scheme 1). Structure 8a is confirmed by a correct elemental analysis, IR, 1H, 13C, 31P NMR, and mass spectra. Its IR spectrum revealed the presence of a strong band at 2182 cm−1, which is ascribed to the N3 absorption [13]. A possible explanation for the course of the formation of compound 8a is shown in Scheme 1. Azidopyrazole 1 reacted with P-ylide 2a to give the intermediate A with expulsion of TPPO. Moreover, intermediate A reacted with another molecule of the ylide 2a yielding intermediate B, which cyclized to intermediate C. Rearrangement of the latter gave the new ylide 8a (Scheme 1). Furthermore, when azidopyrazole 1 was allowed to react with (acetylmethylene)triphenylphosphorane (2b) in dry THF at room temperature, product 8b was separated as colorless crystals with 75% yield (Scheme 1). Elemental and mass spectral analysis of 8b led to an empirical formula C14H13N5O. The IR spectrum displays absorption bands at ν = 1682 (C=O) and 1593 (cyclic C=N) cm−1 but lacks the azido function group around at 2180 cm−1 [13]. The 1H NMR spectrum of 8b gave signals at δ = 1.96 (s, 3H, CH3), at 2.64 ppm (s) for a methyl group attached to the triazole ring, at 7.34–7.54 ppm (m, 6H, Harom, =CH), and a singlet at 9.66 ppm for the aldehydic proton. The 13C NMR spectrum of 8b added a good support for the proposed structure and revealed signals at 8.3 and 13.7 ppm for the two methyl groups, 136.3 and 136.6 ppm (2C, triazole), 123.2–133.2 ppm (aromatic CH), 117.4, 136.7, and 151.6 ppm (quaternary carbon atoms C-4, C-3, C-5 of pyrazole), and 183.4 ppm for a carbonyl group. The reaction presumably proceeds via 1,3-dipolar cycloaddition of the azide group of azidopyrazole 1 to the C=C bond of the ylide 2b followed by loss of TPPO from the cyclic intermediate D to give 1,2,3-triazole derivative 8b [14–16] (Scheme 1). The molecular structure of 8b was also confirmed by X-ray crystallographic analysis. An Ortep diagram of compound 8b is shown in Fig. 2. The crystal data and experimental parameters used for intensity data collection and the final results of the structure refinement are presented in Table 2 (cf. Experimental Section).

The behavior of azidopyrazole 1 toward stabilized phosphonium ylides 2a–c.

Ortep view of 8b with crystallographic atom numbering. Displacement parameters are drawn at the 30% probability level, H as spheres with arbitrary radii. Selected bond lengths (Å) and angles (deg): N1–N2 1.372(3), N3–N4 1.374(4), N4–N5 1.294(4); N1–N2–C6 120.2(2), N1–N2–C11 111.1(2), N3–N4–N5 106.8(3).
Similarly, the Wittig reaction of (dibromomethylene)triphenylphosphorane (2c) with azidopyrazole 1 afforded 4-(2,2-dibromovinyl)pyrazole 8c (Scheme 1). The IR spectrum of 8c revealed the presence of absorption bands at ν = 2125 (N3) [13] and 626 (C–Br) [17] cm−1. The structure of 8c was also deduced from its NMR (1H, 13C) and mass spectra together with correct microanalyses (cf. Experimental Section).
Next, when azidopyrazole 1 was allowed to react with two molar equivalents of diethyl(cyanomethyl)phosphonate (3a) in an ethanolic sodium ethoxide solution at room temperature, products 9a and 9b were obtained (Scheme 2). The most important feature of structure 9a is the presence of a signal at δ = 23.03 (s) ppm in its 31P NMR spectrum and the presence of an IR band at 2114 cm−1, which is ascribed to the N3 absorption [13]. Moreover, the 1H NMR spectrum of 9a revealed a triplet at δ = 1.32 ppm, which indicates CH3 protons of ethyl group with JHH = 13.4 Hz, singlet at 2.63 ppm (3H, CH3), doublet at 2.72 ppm with 2JHP = 22.89 Hz, doublet at 3.47 ppm with 3JHP = 12.5 Hz (CHOH), and two quartet at 4.22 ppm (4H, 3JHP = 12.5 Hz) for CH2 protons of ethyl group.

The behavior of azidopyrazole 1 toward W-H reagents 3a,b.
A possible explanation for the course of the reaction of 1 with Wittig-Horner reagent 3a is shown in Scheme 3. The initial attack of the anion derived from phosphonic ester 3a on the most reactive center of 1 gave product 9avia intermediate E. The assigned product 9b presumably was formed via intermediate F. Under the influence of the base present in the reaction medium, elimination of N2 was followed by hydrolysis F to give 9b and dialkyl phosphite (Scheme 2). The dialkyl phosphite was detected in the water layer by the development of a violet color on addition of 3,5-dinitrobenzoic acid [18]. The assigned cis configuration for 9b is supported by the chemical shift and coupling constant of the two protons CH=CHCN (JHH = 7.6 Hz) (Scheme 2).

Formation mechanism of 9a,b.
The reaction of azidopyrazole 1 with 4-methoxybenzylphosphonate 3b was also investigated. We have found that the reaction of 1 with a molar equivalent of Wittig-Horner reagent 3b in the presence of sodium ethoxide in ethanol afforded the pure 9c (Scheme 2). The structural assignment for compound 9c was based upon elemental analysis and spectroscopic data (cf. Experimental Section). Product 9c can be obtained via intracyclization of azide 1. It has been reported that o-azido-carbaldehyde compounds can be intracyclized with good yield under the influence of a basic medium [19, 20].
The reaction of azidopyrazole 1 with diethyl phosphonate (diethyl hydrogen phosphite) (4) in dry toluene at room temperature gave 5-amino-pyrazole-4-carbaldehyde 10 with 75% yield (Scheme 4). The assignment of structure 10 was based on correct elemental analysis and molecular weight determination (MS), 1H NMR, and IR comparison with an authentic specimen [21].

The behavior of azidopyrazole 1 toward diethylphosphonate 4.
A mechanism that accounts for the reaction of azidopyrazole 1 with diethyl phosphonate (4) is depicted in Scheme 4. The initial attack of the phosphorus lone pair at the azide group with expulsion of a nitrogen molecule gives intermediate G, which decomposes due to the unavoidable moisture to give the aminopyrazole 10 and diethylphosphite (Scheme 4) [21].
We have found that the reaction of trimethyl phosphite (5a) with azidopyrazole 1 in dry toluene proceeded at room temperature to give chromatographically pure adduct 11a (Scheme 5), which was separated as brown crystals (75% yield). The results of elemental analysis and molecular weight determination (MS) of this product correspond to C14H18N3O4P. The 31P NMR spectrum has one signal at δ = 23.2 ppm. The IR spectrum reveals the absence of an N3 band [13] and the presence of both the (C=N) band at 1558 and C=O band at 1658 cm−1. The structure of 11a has also been assigned on the basis of 1H and 13C NMR spectra (cf. Experimental Section). Similarly, when 1 was reacted with 5b in dry toluene at room temperature, the phosphorane imine product 11b was obtained with 85% yield (Scheme 5). Structure elucidation of 11b was derived from its spectral data (cf. Experimental Section).

The behavior of azidopyrazole 1 toward trialkylphosphites 5a,b and trisdialkylaminophosphines 5c,d.
Meanwhile, performing the reaction of 1 with tris(dialkylamino)phosphanes 5c,d led to the formation of the [tris(dialkylamino)phosphoranylidene]triazenes 11c,d (Scheme 5). The structures of 11c,d have also been assigned on the basis of elemental analysis, MS, IR, 1H, 13C, 31P NMR spectral data (cf. Experimental Section). The structure of 11c was also confirmed by X-ray crystallographic analysis. An Ortep diagram of the molecular structure of compound 11c in the crystal is shown in Fig. 3. Furthermore, this study has been extended to include the reaction of azidopyrazole 1 with triphenylstibane (6a) and triphenylarsane (6b) to establish whether they would behave in a similar manner as triphenylphosphane (6c) [22–25]. A different behavior is observed in the reaction of 1 with 6a and 6b, yielding 5-azido-4-(triphenylstiboranylidene)methyl-1H-pyrazole 12a in 75% yield and 4-(triphenylarsoranylidene)methyl-1H-pyrazole 12b in 45% yield with extrusion triphenylstibane oxide and triphenylarsane oxide, respectively (Scheme 6).

Ortep view of 11c with crystallographic atom numbering. Displacement parameters are drawn at the 30% probability level, H atoms as spheres with arbitrary radii. Selected bond lengths (Å) and angles (deg): P1–N5 1.579(4), P1–N6 1.709(4), P1–N7 1.714(4), P1–N8 1.704(4); N5–P1–N6 113.2(4), N5–P1–N7 110.8(4), N6–P1–N7 110.3(4), N5–P1–N8 106.1(4), N6–P1–N8 109.9(4), N7–P1–N8 106.3(4).

The behavior of azidopyrazole 1 toward TPP, TPSb, TPAs 7a–c.
When the pyrazole-4-carbaldehyde 1 was stirred at ambient temperature with LR, the 5-sulfido-1,2,3,4,5-thiatriazaphosphole 13 was obtained in good yield through cycloaddition reaction between the monomeric form of LR 7 and the azido group of 1 [26, 27] (Scheme 7). The elemental microanalysis, 1H, 13C, 31P NMR, and MS data agreed with structure 13.

The behavior of azidopyrazole 1 toward LR 8.
The IR spectrum of structure compound 13 revealed the absence of an N3 absorption band [13] and showed bands at 625 cm−1 (P=S), 1585 cm−1 (C=N), 1696 cm−1 (C=O). The 1H NMR shifts of compound 13 were at δ = 2.46 (s, 3H, CH3), 3.76 (s, 3H, OCH3), and 6.95–7.65 (m, 9H aromatic). The structure assigned to 13 was also based on a 13C NMR spectrum that shows signals of 55.7 (OCH3), 105.0 (quaternary C-4, pyrazole), 113.9–145.5 (aromatic C-H, C-3, and C-5 of pyrazole), and 161.6, 161.7 (C=O) ppm.
2.2 Description of the crystal and molecular structures of 8b and 11c
Ortep plots of the molecular structures of compounds 8b and 11c are shown in Figs. 2 and 3, respectively. Both compounds crystallize in the monoclinic system possessing four molecules in the unit cell with space groups Cc for 8b and P2/n for 11c. The asymmetric unit in the two structures contains only one molecule. In 8b, there is a significant twist between the pyrazole ring and both attached triazole and benzene rings with the dihedral angles being 49.9(2)° and 62.3(2)°, respectively. The same is observed in compound 11c, with a significant twist between the pyrazole ring and the attached benzene ring with the dihedral angle being 38.4(2)°. An important feature to note in 8b is that the molecules are linked into chains by one weak hydrogen bond of the C–H···O type and a set of H···π and O···π interactions as listed in Table 1 and illustrated in Fig. 4. Molecules 11c are linked into chains by one hydrogen bond of the C–H···O type listed in Table 2 and illustrated in Fig. 5.
Hydrogen bond geometry and non-bonding contacts (Å, deg) of compound 8b.a
D–H···A | D–H | H···A | D···A | D–H···A |
---|---|---|---|---|
C14–H142···O1i | 0.95 | 2.55 | 3.499(5) | 175 |
C1–H11···Cg2 | 0.95 | 2.99 | 3.469(4) | 113 |
Y–X···Cg | Y–X | X···Cg | Y···Cg | Y–X···Cg |
C10–O1··· Cg1i | 1.207(4) | 3.195(3) | 3.430(4) | 90.7(2) |
aSymmetry codes: (i) x, 1 – y, –1/2 + z; Cg1 = N1–N2–C11–C9–C7; Cg2 = N3–N4–N5–C12–C13.

Packing of the molecules in the unit cell of compound 8b showing various types of intermolecular interactions as dashed lines.
Hydrogen bond geometry and non-bonding contacts (Å, deg) of compound 11c.a
D–H···A | D–H | H···A | D···A | D–H···A |
---|---|---|---|---|
C17–H173···O1i | 0.95 | 2.34 | 3.273(14) | 165 |
aSymmetry code: (i) 3/2 – x, 1/2 + y, 3/2 – z.

Packing of the molecules in the unit cell of compound 11c showing weak hydrogen bonds as dashed lines.
2.3 Anticancer screening
Cancer is one of the diseases with a high mortality rate [28]. The current trend of research focuses on investigating the biological activity of newly synthesized compounds, aiming to develop new anticancer drugs. Derivatives of pyrazole have received considerable attention owing to their diverse chemotherapeutic potentials including their versatile anticancer activities [7]. Thus, the current study was tailored to screen invitro cytotoxic and growth inhibitory activities of most of the newly synthesized azidopyrazole compounds on human breast carcinoma cell line (MCF7) and human hepatocellular carcinoma cell line (HepG2). MCF7 and HepG2 cells were cultured as monolayers and treated with our compounds for 48 h. The rate of proliferation was assessed by the Alamar blue reduction assay. According to current data, compounds 8a, 8b, 9a, and 9b demonstrate a higher antitumor activity against MCF7 cells with low cytotoxic activity (IC50 = 10.12, 1.012, 8.56, and 8.36 μm, respectively) than that of the reference drug (doxorubicin, IC50 = 10.2 μm) (Table 3). Meanwhile, azidopyrazole derivatives showed less antitumor activity against HepG2 cells with higher IC50 than doxorubicin (IC50 = 5.61 μm). The study revealed that azidopyrazole derivatives have a potential antitumor activity against MCF7 cells; however, those derivatives are less potent against HepG2 cells. In addition, the current data stressed that compounds 9a, 9b, and 8b have the most effective antitumor activity. Compound 8b has a triazole ring that was previously reported to have a potentially broad range of biological and pharmacological activities [29]. Additionally, compounds 9a and 9b have a significant antitumor activity that may be associated with presence of the nitrile (CN) group, which has previously been reported to have a strong biological activity due to their strong hydrogen bond acceptor leading to strong versatile interactions with different proteins [30]; therefore, compounds 9a, 9b, and 8b have promising therapeutic effects that can be further studied invivo and invitro.
Cytotoxic activity of azidopyrazole derivatives against MCF7 and HepG2.
Compounds | MCF7 IC50 (μm) | HepG2 IC50 (μm)a |
---|---|---|
Doxorubicinb | 10.2 ± 0.13 | 5.61 ± 0.037 |
1 | 21.27 ± 0.85 | 18.94 ± 2.14 |
8a | 10.12 ± 0.65 | 12.52 ± 0.220 |
8b | 1.012 ± 0.13 | 24.1 ± 1.78 |
9a | 8.56 ± 0.23 | 20.1 ± 0.42 |
9b | 8.36 ± 0.11 | 16.88 ± 0.29 |
11a | 19.31 ± 1.65 | 14.85 ± 0.39 |
11b | 13.33 ± 0.28 | 25.96 ± 1.39 |
11c | 24.33 ± 0.17 | 12.99 ± 4.81 |
11d | 24.78 ± 1.75 | 19.42 ± 1.29 |
12a | 15.22 ± 0.92 | 16.31 ± 0.23 |
12b | 26.23 ± 0.88 | 36.46 ± 0.86 |
12c | 24.09 ± 0.60 | 12.58 ± 5.34 |
13 | 32.23 ± 0.38 | 37.6 ± 0.13 |
aIC50 value was defined as the concentration at which 50% survival of cells was observed and it is expressed as mean ± SE. DMSO was used as negative control. bDoxorubicin was used a reference drug.
3 Conclusion
The reaction of 5-azido-3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde (1) with phosphonium ylides 2a–c led to different products 8a–c depending on the nature of the phosphonium ylides as well as the stability of the addition products. The reaction of 1 with Wittig-Horner reagents 3a and 3b gave different product 9a,b and 9c depending on the nature of the methane phosphonate anion as well as the stability of the addition products. In the reaction of 1 with diethyl phosphonate, 4,5-amino-3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde (10) and dialkyl phosphite were the sole reaction products. The reaction of azidopyrazole 1 with trialkyl phosphites 5a,b and tris(dialkylamino)phosphines 5c,d yielded different products. These processes can be considered as new and simple routes for the preparation of various organophosphorus and heterocyclic compounds that cannot be obtained by other conventional methods. The compounds have shown promising anticancer activities against the human breast cancer cell lines (MCF7) at very low concentrations.
4 Experimental section
4.1 Chemistry
Melting points were determined in open glass capillaries using an Electrothermal IA 9100 series digital melting point apparatus (Electorthermal, Essex, UK), IR spectra were measured as KBr pellets with a Perkin-Elmer infracord spectrophotometer model 157. The 1H and 13C NMR spectra were recorded in CDCl3 or [D6]dimethyl sulfoxide (DMSO) as solvents on a Jeol-500 spectrometer (1H: 500 MHz; 13C: 125 MHz), and the chemical shifts are recorded in δ values relative to TMS as internal reference. The 31P NMR spectra were taken with a Varian CFT-20 spectrometer (vs. external 85% H3PO4 as standard). The mass spectra were recorded at 70 eV with a Kratos MS equipment or Varian MAT 311A spectrometer. Elemental analyses were performed using an Elementar Vario E1 instrument. The reported yields are of pure isolated materials obtained by column chromatography on silica gel 60 (Merk). 5-Azido-3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde (1) was prepared according to a reported method [31, 32].
4.2 Reaction of (cyanomethylene)triphenylphosphorane (2a) with 1
A mixture of 2a (0.60 g, 2 mmol) and 0.27 g (1 mmol) of 1 in dry THF (30 mL) was stirred for 1h. The volatile material was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography to give product 8a. TPPO was also isolated and identified.
4.2.1 2-((5-Azido-3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl)-3-(triphenylphosphoranylidene)succinonitrile (8a)
Eluent: petroleum ether-ethyl acetate (70:30, v/v). Product 8a was separated as deep red crystals, yield 85%; m.p. 262°C–263°C. – IR (KBr): ν = 1587 (cyclic C=N), 2182 (N3), 2235, 2364 (2 CN) cm−1. – 1H NMR (300 MHz, DMSO): δ = 1.76 (s, 3 H, CH3), 1.99 (t, 1H, CH), 3.60 (d, 2 H, CH2), 7.65–7.84 (m, 20H, Harom) ppm. – 13C NMR (75 MHz, DMSO): δ = 14.6 (CH3), 25.6 (CH2), 67.5 (CH), 99.9 (C-4, pyrazole), 115.8, 118.21 (2 CN), 121.5, 121.6 (C=P, Jc,p = 98.5 Hz),118.4–144.2 (aromatic C–H, C-3, C-5 of pyrazole) ppm. – 31P NMR: δ = 21.88 ppm. – MS (EI, 70 eV): m/z (%) = 551(5) [M]+, 384 (100) [M–167]+. – C33H26N7P (551.58): calcd. C 71.86, H 4.75, N 17.78, P 5.62; found C 71.89, H 4.77, N 17.98, P 5.72.
4.3 Reaction of (acetylmethylene)triphenylphosphorane (2b) with 1
A mixture of 1 mmol of 2b (0.31 g) and 1 mmol of 1 (0.27 g) in dry THF (30 mL) was stirred for 2 h. The volatile material was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography to give product 8b. TPPO was also isolated and identified.
4.3.1 3-Methyl-5-(5-methyl-1H-1,2,3-triazol-1-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde (8b)
Eluent: petroleum ether-ethyl acetate (80:20, v/v). Product 8b was separated as colorless crystals, yield 75%; m.p. 99°C–101°C. – IR (KBr): ν = 1593 (C=N), 1682 (C=O) cm−1. – 1H NMR (500 MHz, CDCl3): δ = 1.96 (s, 3H, CH3), 2.64 (s, 3 H, CH3), 7.34–7.54 (m, 6H, Harom, =CH), 9.66 (s, 1H, CHO)ppm. – 13C NMR (125 MHz, CDCl3): δ = 8.3 (CH3), 13.7 (CH3), 136.3, 136.6 (2C, triazole), 123.2–133.2 (aromatic CH), 117.4, 136.7, 151.6 (C-4, C-3, C-5of pyrazole), 183.4 (CHO) ppm. – MS (EI, 70 eV): m/z (%) = 268 (10) [M+1]+, 267(8) [M]+. – C14H13N5O (267.29): calcd. C 62.91, H 4.90, N 26.20; found C 62.95, H 4.87, N 26.18.
4.4 Reaction of (dibromomethylene)triphenylphosphorane (2c) with 1
Triphenylphosphane (0.5 g, 0.1 mmol) was added to a well-stirred solution of carbon tetrabromide (0.3 g, 0.05 mL) in DCM (3 mL). When the solution became orange (i.e. 2c was formed) [33], pyrazole 1 (0.27 g, 0.1 mmol) was added, and the mixture was stirred at room temperature for 8 h. After evaporation of the volatile material, the buff residual substance was chromatographed on a silica gel column. TPPO was also isolated and identified.
4.4.1 5-Azido-4-(2,2-dibromovinyl)-3-methyl-1-phenyl-1H-pyrazole (8c)
Eluent: petroleum ether-ethyl acetate (80:20, v/v). Product 8c was separated as buff powder, yield 35%. – m.p. 158°C–161°C. – IR (KBr): ν = 626 (C–Br), 1593 (C=N), 2125 (N3) cm−1. – 1H NMR (500 MHz, [D6]DMSO): δ = 2.04 (s, 3H, CH3), 7.58–7.99 (m, 6H, Harom), 8.59 (s, 1H, CH) ppm. – 13C NMR (125 MHz, [D6]DMSO): δ = 13.8 (CH3), 99.8 (=C(Br)2), 100.2 (C-4, pyrazole), 124.8–140.3 (aromatic C–H), 135.2, 150.3 (C-3, C-5 of pyrazole) ppm. – MS (EI, 70 eV): m/z (%) = 380, 382, 384 [1:2:1] (15). – C12H9Br2N5 (383.04): calcd. C 37.63, H 2.37, Br 41.72, N 18.28; found C 37.71, H 2.23, Br 41.64, N 18.19.
4.5 Reaction of diethyl cyanomethylphosphonate (3a) or diethyl 4-methoxybenzylphosphonate (3b) with 1
A solution of sodium ethoxide (0.14 g, 2 mmol) in absolute ethanol (30 mL) was treated with an equimolar amount of diethyl (cyanomethyl)phosphonate (3a) or diethyl 4-(methoxybenzyl)phosphonate (3b) (2 mmol). Azidopyrazole 1 (0.27 g, 1 mmol) was added, and the reaction mixture was stirred at room temperature for 4 h (TLC). The mixture was poured on a small amount of water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and the extracts were evaporated under reduced pressure. The residue was applied to silica gel column chromatography to give compounds 9a,b and/or 9c.
4.5.1 Diethyl 2-(5-azido-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-cyano-2-hydroxyethylphosphonate (9a)
Eluent: petroleum ether-ethyl acetate (80:20, v/v). Product 9a was separated as pale yellow crystals, yield 20%; m.p. 86°C–87°C. – IR (KBr): ν = 1024 (P=O), 1592 (C=N), 2114 (N3), 2359 (CN), 3441 (OH) cm−1. – 1H NMR (500 MHz, CDCl3): δ = 1.32 (t, 6H, JHH = 13.4 Hz, P–OCH2CH3), 2.63 (s, 3H, CH3), 2.72 (d, 1H, CH–P, 2JHP = 22.9 Hz), 3.47 (d, 1H, 3JHP = 12.5 Hz, CHOH), 4.22 (2q, 4H, 3JHP = 12.5 Hz, P–O–CH2),7.92–8.72 (m, 5H, Harom), 8.96 (s, 1H, OH) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.6 (CH3), 16.4 (O–CH2–CH3), 40.5 (C–P, JC–P = 125 Hz), 63.58, 64.49 (CH2), 69.73 (CH–OH), 101.9 (CN), 104.5 (C-4, pyrazole), 124.2–144.6 (aromatic C–H, C-3, C-5 of pyrazole) ppm. – 31P NMR: δ = 23.03 ppm. – MS (EI, 70 eV): m/z (%) = 386 (100) [M–OH]+. – C17H21N6O4P (404.36): calcd. C 50.50, H 5.23, N 20.78, P 7.66; found C 50.48, H 5.11, N 20.66, P 7.93.
4.5.2 (Z)-3-(5-Amino-3-methyl-1-phenyl-1H-pyrazol-4-yl)acrylonitrile (9b)
Eluent: petroleum ether-ethyl acetate (70:30, v/v). Product 9b was separated as buff crystals, yield 40%; m.p. 165°C–166°C. – IR (KBr): ν = 1599 (C=N), 2362 (CN), 3362, 3302, 3205 (NH2) cm−1. – 1H NMR (500 MHz, CDCl3): δ = 2.55 (s, 3H, CH3), 6.47 (d, 1H, J = 7.6 Hz, CHCN), 7.76 (1H, CH=CH, JHH = 7.6 Hz), 7.92–8.72 (m, 7H, Harom, NH2) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (CH3), 98.5 (C–CN), 112.5 (C-4, pyrazole), 123.2–149.6 (aromatic C–H, C-3, C-5 of pyrazole) ppm. – MS (EI, 70 eV): m/z (%) = 224(5) [M]+. – C13H12N4 (224.26): calcd. C 69.62, H 5.39, N 24.98; found C 69.73, H 5.42, N 25.01.
4.5.3 5-Methyl-7-phenyl-3H-pyrazolo[3,4-d][1,2,3]triazin-4(7H)-one (9c)
Eluent: petroleum ether-ethyl acetate (95:5, v/v). Product 9c was separated as orange crystals, yield 65%; m.p. 160°C–162°C. – IR (KBr): ν = 3334 (NH), 1672 (C=O), 1665 (N=N), 1619 (C=C), 1596 (C=N) cm−1. – 1H NMR (500 MHz, CDCl3): δ = 2.36 (s, 3 H, CH3), 4.51 (s, 1 H, NH, exchangeable with D2O), 7.45–7.57 (m, 5 H, CHarom) ppm. – 13C NMR (CDCl3): δ = 14.3 (CH3), 96.3, 152.5 (cyclic C=C), 124.9–138.7 (aromatic, C–H), 149.2 (C=N), 162.4 (C=O) ppm. – MS (EI, 70 eV): m/z (%) = 227 (50) [M]+. – C11H9N5O (227.22): calcd. C 58.14, H 3.99, N 30.82; found: C 58.12, H 4.01, N 30.74.
4.6 Reaction of diethyl hydrogenphosphite (4) with 1
A mixture of 1 mmol of 4 (0.17g) and 1 mmol of 1 (0.27 g) in dry toluene (30 mL) was stirred for 30 min. After evaporation of the volatiles under reduced pressure, the residue was subjected to silica gel column chromatography to yield structure 10.
4.6.1 5-Amino-3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde (10)
Eluent: petroleum ether-ethyl acetate (80:20, v/v). Product 10 was separated as colorless crystals, yield 75%; m.p. 96°C–98°C. – IR (KBr): ν = 1543 (C=N), 1606 (C=C), 1644 (C=O), 3398, 3288, 3187 (NH2) cm−1. – 1H NMR (500 MHz, CDCl3): δ = 2.64 (s, 3 H, CH3), 5.32 (s, 2H, NH2 exchangeable with D2O), 7.34–7.54 (m, 5H, Harom), 9.66 (s, 1H, CHO) ppm. – MS (EI, 70 eV): m/z (%) = 201.22 (100) [M]+. Compound 10 gave a correct elemental analysis and it was characterized by TLC analysis (one spot) and IR comparison with an authentic specimen [21].
4.7 Reaction of trialkylphosphite (5a,b) with 1
A mixture of 1 mmol of 5a or 5b and 1 mmol of 1 in dry toluene (30 mL) was stirred for 1–2 h (TLC). After evaporation of the volatile material, the residue was recrystallized from a proper solvent to yield compound 11a,b.
4.7.1 Trimethyl (4-formyl-3-methyl-1-phenyl-1H-pyrazol-5-yl)phosphoramidate (11a)
Product 11a was separated as brown crystals (benzene), yield 75%; m.p. 238°C–239°C. – IR (KBr): ν = 1063 (P–O–alkyl), 1558 (C=N), 1658 (C=O) cm−1. – 1H NMR (500 MHz, CDCl3): δ = 2.66 (s, 3H, CH3), 3.36–3.52 (d, 3JHP = 11.0 Hz, 9H, P(OCH3)3), 7.25–7.97 (m, 5H, Harom), 10.24 (s, H, CHO) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.9 (CH3), 54.9, 55.1 (d, 2JCP = 11 Hz, P–(OCH3)3), 104.5 (C-4, pyrazole), 123.2–152.6 (aromatic C–H, C-3, C-5 of pyrazole), 179.4 (C=O) ppm. – MS (EI, 70 eV): m/z (%) = 323 (35) [M]+. – 31P NMR δ = 23.2 ppm. – C14H18N3O4P (323.28): calcd. C 52.01, H 5.61, N 13.00, P 9.58; found C 52.21, H 5.66, N 13.11, P 9.32.
4.7.2 Triisopropyl (4-formyl-3-methyl-1-phenyl-1H-pyrazol-5-yl)phosphorimidate (11b)
Product 11b was separated as brown crystals (benzene), yield 85%; m.p. 257°C–259°C. – IR (KBr): ν = 1082 (P–O–alkyl), 1592 (C=N), 1655 (C=O) cm−1. – 1H NMR (500 MHz, CDCl3): δ =1.26 (m, 18H, 3 CH(CH3)2), 2.46 (s, 3H, CH3), 3.96 (m, 3H, CH, 3 CH(CH3)2), 7.22–7.83 (m, 5H, Harom), 10.11 (s, H, CHO) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.9 (CH3), 22.8 (CH3, 3 CH(CH3)2), 74.2 (d, 2JCP = 11 Hz, P–O–CH), 104.5 (C-4, pyrazole), 123.3–152.5 (aromatic C–H, C-3, C-5 of pyrazole), 179.4 (C==O) ppm. – 31P NMR: δ = 23.7 ppm. – MS (EI, 70 eV): m/z (%) = 407 (100) [M]+. – C20H30N3O4P (407.44): calcd. C 58.96, H 7.42, N 10.31, P 7.60; found C 59.00, H, 7.22, N, 10.52, P7.61.
4.8 Reaction of tris(dialkylamino)phosphanes 5c,d with 1
A mixture of 5c or 5d (1 mmol) and 0.27 g (1 mmol) of 1 in dry benzene (30 mL) was stirred for 3 h. After evaporation of the volatile material under reduced pressure, the residue was subjected to silica gel column chromatography to yield 11c,d.
4.8.1 3-Methyl-1-phenyl-5-[(tris(dimethylamino)phosphoranylidene]triaz-1-en-1-yl)-1H-pyrazole-4-carbaldehyde (11c)
Eluent: petroleum ether-ethyl acetate (80:20, v/v). Product 11c was separated as yellow crystals, yield 75%; m.p. 140°C–142°C. – IR (KBr): ν =1599 (C=N), 1651 (C=O), 1665 (N=N) cm−1. – 1H NMR (300 MHz, CDCl3): δ = 2.36 (s, 3 H, CH3), 2.50, 2.64, 3.36 (d, 3JHP = 9.3 Hz, 18H, P[N(CH3)2]3), 7.33–7.69 (m, 5H, Harom), 9.71 (s, H, CHO) ppm. – 13C NMR (75 MHz, CDCl3): δ = 14.8 (CH3), 37.0 (N(CH3)2), 110.8 (C-4, pyrazole), 124.7–149.6 (aromatic C–H, C-3, C-5 of pyrazole), 186.9 (C=O) ppm. – 31P NMR: δ = 29.8 ppm. – MS (EI, 70 eV): m/z (%) = 390 (10) [M]+. – C17H27N8OP (390.42): calcd. C 52.30, H 6.97, N 28.70, P 7.93; found C 52.23, H 6.82, N 28.73, P 7.87.
4.8.2 3-Methyl-1-phenyl-5-[(tris(diethylamino)phosphoranylidene]triaz-1-en-1-yl)-1H-pyrazole-4-carbaldehyde (11d)
Eluent: petroleum ether-ethyl acetate (80:20, v/v). Product 11d was separated as colorless crystals, yield 60%; m.p. 153°C–155°C. – IR (KBr): ν = 1599 (C=N), 1664 (N=N), 1728 (C=O) cm−1. – 1H NMR (500 MHz, CDCl3): δ = 1.06–1.19 (m, 18H, CH3), 2.48 (s, 3 H, CH3), 2.99–3.03 (q, 12H, CH2), 7.47–7.96 (m, 5H, Harom), 9.93 (s, H, CH=O) ppm. – 13C NMR (125 MHz, CDCl3): δ = 12.21 (CH3), 19.34 (N(CH3)2), 46.73 (N(CH2)2), 118.9 (C-4, pyrazole), 126.0–152.6 (aromatic C–H, C-3, C-5 of pyrazole), 167.7 (C=O) ppm. – 31P NMR: δ = 25.8 ppm. – MS (EI, 70 eV): m/z (%) = 474 (15) [M]+. – C23H39N8OP (474.58): calcd. C 58.21, H 8.28, N 23.61, P 6.53; found C 58.31, H 8.31, N 23.54, P 6.23.
4.9 Reaction of triphenylstibane/triphenylarsane 6a,b with 1
A mixture of 6a or 6b (1 mmol) and 0.27 g (1 mmol) of 1 in dry toluene (30 mL) was warmed for 1–4 h (TLC). After evaporation of the volatile material, the buff residual substance was recrystallized from benzene to yield 12a,b and triphenylstibane oxide, triphenylarsane oxide were isolated and identified (m.p. and mixed m.p.).
4.9.1 5-Azido-3-methyl-1-phenyl-4-[(triphenylstiboranylidene)methyl]-1H-pyrazole (12a)
Product 12a was separated as buff crystals (benzene), yield 75%; m.p. 236°C–238°C. – IR (KBr): ν =1593 (C=N), 2195 (N3) cm−1. – 1H NMR (500 MHz, [D6]DMSO):δ = 1.99 (s, 3 H, CH3), 6.90 (s, 1H, CH), 7.33–7.68 (m, 20H, Harom) ppm. – 13C NMR (75 MHz, [D6]DMSO): δ = 14.5 (CH3), 70.0 (CH), 117.8 (C-4, pyrazole), 120.5–148.6 (aromatic C–H, C-3, C-5 of pyrazole), 166.7 (C=O) ppm. – MS (EI, 70 eV): m/z (%) = 564(5) [M]+, 429 (15) [M–135]+. – C29H24N5Sb (564.29): Sb 21.58, Sb 21.60.
4.9.2 5-Azido-3-methyl-1-phenyl-4-((triphenylarsoranylidene)methyl)-1H-pyrazole (12b)
Product 12b was separated as buff crystals (benzene), yield 45%; m.p. 211°C–213°C. – IR (KBr): ν =1592 (C=N), 2196 (N3) cm−1. – 1H NMR (500 MHz, CDCl3): δ = 2.36(s, 3 H, CH3), 7.25–7.57 (m, 21H, Harom, CH) ppm. – 13C NMR (125 MHz, CDCl3): δ = 14.2 (CH3), 70.07 (CH), 117.9 (C-4, pyrazole), 122.5–149.6 (aromatic C–H, C-3, C-5 of pyrazole), 169.7 (C=O) ppm. – MS (EI, 70 eV): m/z (%) = 517(5) [M]+. – C29H24AsN5 (517.46): As 14.48, As 14.50.
4.10 Reaction of LR 7 with 1
A mixture of 0.20 g (0.5 mmol) of 7 and 0.27 g (1 mmol) of 1 was stirred for 15 min in dry benzene. The volatile material was evaporated under reduced pressure. The precipitate was filtered off and washed with diethyl ether, then recrystallized from benzene to afford product 13.
4.10.1 5-[5-(4-Methoxyphenyl)-5-sulfido-1,2,3,4,5-thiatriazaphosphol-2(5H)-yl]-3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde (13)
Compound 13 was isolated as buff powder, yield 65%; m.p. 144°C–146°C. – IR (KBr): ν = 625 (P=S), 1585 (C=N), 1696 (C=O) cm−1. – 1H NMR (500 MHz, [D6]DMSO): δ = 2.46 (s, 3H, CH3), 3.76 (s, 3H, OCH3), 6.95–7.65 (m, 9H, Harom) ppm. – 13C NMR (125 MHz, [D6]DMSO): δ = 12.1 (CH3), 55.7 (OCH3), 105.0 (C-4, pyrazole), 113.9–145.5 (aromatic C–H, C-3, C-5 of pyrazole), 161.6, 161.7 (C=O) ppm. – 31P NMR: δ = 15.0 ppm. – MS (EI, 70 eV): m/z (%) = 429(5) [M]+. – C18H16N5O2PS2 (429.46): calcd C 50.34, H 3.76, N, 16.31, P 7.21, S 14.93; found: C 55.30, H 3.78, N 16.32, P 7.23, S 14.91.
4.11 Crystal structure determinations of 8a and 11c
Single crystals of 8a and 11c were grown by crystallization from benzene. The diffraction data were collected on an Enraf-Nonius 590 diffractometer with a Kappa CCD detector using graphite-monochromatized MoKα (λ = 0.71073 Å) radiation at National Research Center of Egypt [34, 35]. Reflection data have been recorded in the rotation mode using the ϕ and ω scan technique with θmax = 34.98° for 8a and 30.04° for 11c. Unit cell parameters were determined from least-squares refinement with θ in the range 4 ≤ θ ≤ 34° for 8a and 3 ≤ θ ≤ 30° for 11c. The structures of 8a and 11c were solved by Direct Methods using Superflip [36] implemented in the program suit Crystals [37]. The refinement was carried out by full-matrix least-squares method on the positional and anisotropic temperature parameters of all non-hydrogen atoms based on F2 using Crystals. All hydrogen atoms were positioned geometrically and were initially refined with soft restraints on the bond lengths and angles to regularize their geometry (C–H in the range 0.93–0.98 Å and N–H in the range 0.86–0.89 Å) and Uiso(H) = 1.2–1.5 × Ueq of the parent atom. Then, the positions were refined with riding constraints [38]. The general-purpose crystallographic tool Platon [39] was used for the structure analysis and presentation of the results. The molecular graphics were done using Ortep-iii for Windows [40] and Diamond [41]. Details of the data collection conditions and the parameters of the refinement process for 8a and 11c are given in Table 4.
Crystal data and experimental parameters of data collection and structure refinement of compounds 8b and 11c.
8b | 11c | |
---|---|---|
Crystal data | ||
Chemical formula | C14H13N5O | C17H27N8OP |
Mr | 267.292 | 390.43 |
Temperature, K | 298 | 298 |
Crystal size, mm3 | 0.12 × 0.13 × 0.15 | 0.14 × 0.15 × 0.18 |
Crystal system, space group | Monoclinic, Cc | Monoclinic, P21/n |
a, Å | 11.9497(10) | 10.8101(4) |
b, Å | 14.8959(13) | 13.3926(5) |
c, Å | 7.7132(8) | 15.6394(8) |
β, deg | 96.245(5) | 107.0286(12) |
V, Å3 | 1364.8(2) | 2164.93(16) |
Z | 4 | 4 |
Radiation type | MoKα | |
μ, mm−1 | 0.09 | 0.15 |
Data collection | ||
Diffractometer | Nonius Kappa CCD diffractometer | |
Absorption correction | Multi-scan | |
Tmin/Tmax | 0.85/1.00 | 0.83/1.00 |
Refl. measured/unique | 2843/2621 | 6100/3100 |
Refl. obeserved [I > 2.0 σ(I)] | 1097 | 1425 |
(sinθ/λ)max, Å−1 | 0.807 | 0.704 |
Refinement | ||
No. of reflections/parameters | 1097/153 | 1425/142 |
R[F2 > 2 σ(F2)]/wR (F2) | 0.043/0.090 | 0.056/0.131 |
x (Flack) | –3(6) | – |
S | 0.95 | 0.90 |
Δρmax/min, e Å−3 | 0.16/–0.15 | 0.25/–0.29 |
CCDC 1415329 (8a) and 1415326 (11c) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre viawww.ccdc.cam.ac.uk/data_request/cif.
4.12 Anticancer evaluation
4.12.1 Cell culture and treatment
All reagents were handled as previously reported [42–44] in a sterile fume hood. DMEM medium and fetal bovine serum (FBS) were purchased from Gibco; phosphate-buffered saline (PBS), pH 7.4, and trypsin-EDTA were obtained from Sigma-Aldrich. Alamar blue or Resazurin (Promega, Mannheim, Germany) reduction assay was used to assess the cytotoxicity of the studied samples. The growth medium (DMEM medium with 10% FBS, 100 U/mL penicillin, and 100 mg/L streptomycin) and Alamar blue were stored at 48°C, whereas trypsin-EDTA and FBS were stored frozen at –80°C and thawed before use; PBS was stored at room temperature. The MCF7 and HepG2 were obtained from the German Cancer Research Center (DKFZ).Cells were cultured in 50-cm2 culture flasks (Corning) using DMEM medium supplemented with 10% FBS, penicillin (100 IU/ml), and streptomycin (100 mg/ml). The culture was maintained at 37°C in an atmosphere of 5% CO2 and 95% relative humidity. The cells were transferred to a new flask every 2 days and treated with trypsin–EDTA to detach them from the flask. Cells were counted under a microscope using a hemacytometer (Hausser Scientific). Cell solutions were diluted with growth medium to a concentration of 1 × 105 cells/mL, transferred to a 96-well plate, and treated with gradient concentrations of test compounds.
4.12.2 Resazurin cell growth inhibition assay
Alamar blue or Resazurin (Promega) reduction assay was used to assess the cytotoxicity of the studied samples. The assay tests the cellular viability and mitochondrial function. Briefly, adherent cells were grown in tissue culture flasks, and then harvested by treating the flasks with 0.025% trypsin and 0.25 mm EDTA for 5 min. Once detached, cells were washed and counted, and an aliquot (5 × 103 cells) was placed in each well of a 96-well cell culture plate with a total volume of 100 μL. Cells were allowed to attach overnight and then treated with samples. The final concentration of samples ranged from 0 to 100 μm. After 48 h, 20 μL of Resazurin 0.01% w/v solution was added to each well, and the plates were incubated at 37°C for 1–2 h. Fluorescence was measured on an automated 96-well Infinite M2000 Pro™ plate reader (Tecan, Crailsheim, Germany) using an excitation wavelength of 544 nm and an emission wavelength of 590 nm. After 48 h incubation, plates were treated with Resazurin solution as mentioned above. Doxorubicin was used as a positive control, and its IC50 was 10.2 ± 0.13 μm against MCF7 cells and 5.61 ± 0.037 μm against HepG2 cells. Each assay was done at least three times, with two replicates each. The viability was compared based on a comparison with untreated cells. IC50 (on cancer cells) was the concentration of the sample required to inhibit 50% of cell proliferation and were calculated from a calibration curve by a linear regression using Microsoft Excel.
Acknowledgments:
The authors thank the National Research Centre (NRC), for the financial support through scientific project no. 10050002, the Cell Culture Unit at Ain-Shams University, and Associate Professor M. Youns, Biochemistry Department, Faculty of Pharmacy, Helwan University, for antitumor screening.
References
[1] L. F. Tietze, A. Steinmetz, F. Balkenhohl, Bioorg. Med. Chem. Lett.1997, 7, 1303.10.1016/S0960-894X(97)00209-6Search in Google Scholar
[2] P. Grosche, A. Höltzel, T. B. Walk, A. W. Trautwein, G. Jung, Synthesis1999, 1999, 1961.10.1055/s-1999-3619Search in Google Scholar
[3] A. Chauhan, P. K. Sharma, N. Kaushik, Int. J. ChemTech Res.2011, 3, 11.Search in Google Scholar
[4] J. Regan, S. Breitfelder, P. Cirillo, T. Gilmore, A. G. Graham, E. Hickey, B. Klaus, J. Madwed, M. Moriak, N. Moss, C. Pargellis, S. Pav, A. Proto, A. Swinamer, L. Tong, C. Torcellini, J. Med. Chem.2002, 45, 2994.10.1021/jm020057rSearch in Google Scholar PubMed
[5] I. Vujasinovic, A. Paravic-Radicevic, K. Mlinaric-Majerski, K. Brajsa, B. Bertosa, Bioorg. Med. Chem. 2012, 20, 2101.10.1016/j.bmc.2012.01.032Search in Google Scholar PubMed
[6] P. Pevarello, M.G. Brasca, R. Amici, P. Orsini, G. Traquandi, L. Corti, C. Piutti, P. Sansonna, M. Villa, B. S. Pierce, M. Pulici, P. Giordano, K. Martina, E. L. Fritzen, R. A. Nugent, E. Casale, A. Cameron, M. Ciomei, F. Roletto, A. Isacchi, G. Fogliatto, E. Pesenti, W. Pastori, A. Marsiglio, K. L. Leach, P. M. Clare, F. Fiorentini, M. Varasi, A. Vulpetti, M. A. Warpehoski, J. Med. Chem.2004, 47, 3367.10.1021/jm031145uSearch in Google Scholar PubMed
[7] S. Manfredini, R. Bazzanini, P. G. Baraldi, M. Guarmeri, D. Simoni, M. E. Marongiu, A. Pani, P. La Colla, E. Tramontano, J. Med. Chem. 1992, 35, 917.10.1021/jm00083a017Search in Google Scholar PubMed
[8] L. S. Boulos, E. F. Ewies, A. F. M. Fahmy, Z. Naturforsch.2011, 66b, 1056.10.1515/znb-2011-1011Search in Google Scholar
[9] L. S. Boulos, H. A. Abdel-Malek, N. F. El-Sayed, Z. Naturforsch.2012, 67b, 243.10.1515/znb-2012-0311Search in Google Scholar
[10] L. S. Boulos, H. A. Abdel-Malek, N. F. El-Sayed, Phosphorus Sulfur Silicon Relat. Elem.2012,187, 697.10.1080/10426507.2011.642432Search in Google Scholar
[11] L.S. Boulos, M. H. N. Arsanious, E. F. Ewies, R. Fatem, Z. Naturforsch. 2008, 63b, 1211.10.1515/znb-2008-1012Search in Google Scholar
[12] N. F. El-Sayed, E. F. Ewies, L.S. Boulos, Res. J. Pharm., Bio. Chem. Sci.2014, 5, 926.Search in Google Scholar
[13] R. M. Silverstein, G. C. Bassler, T. C. Morrill, Spectrometric Identification of Organic Compounds, John Wiley & Sons, New York, 1991, p. 430.Search in Google Scholar
[14] L. S. Boulos, S. S. Maigali, Egypt. J. Chem. 2010, 53, 203.10.21608/ejchem.2010.1212Search in Google Scholar
[15] G. R. Harvey, J. Org. Chem. 1966, 31, 1587.10.1021/jo01343a063Search in Google Scholar
[16] P. Ykman, G. L’abbé, G. Smets, Tetrahedron, 1971, 27, 845.10.1016/S0040-4020(01)92481-0Search in Google Scholar
[17] L. J. Bellamy, The Infrared Spectra of Complex Molecules, John Wiley & Sons, New York, 1959, p. 328.Search in Google Scholar
[18] B. C. Saunders, B. P. Stark, Tetrahedron1958, 4, 169.10.1016/0040-4020(58)88015-1Search in Google Scholar
[19] M. A. Abd-El-Maksoud, S. S. Maigali, F. M. Soliman, J. Heterocycl. Chem.2014, 51, 1830.10.1002/jhet.2205Search in Google Scholar
[20] T. C. Porter, R. K. Smalley, M. Teguiche, B. Purwono, Synthesis, 1997, 1997, 773.10.1055/s-1997-1416Search in Google Scholar
[21] Y. O. El-Khoshieh, Phosphorus Sulfur Silicon Relat. Elem.1998, 139, 163.10.1080/10426509808035685Search in Google Scholar
[22] N. Panda, S. Karmakar, A. K. Jena, Chem. Heterocyclic Comp.2011, 46, 1500.10.1007/s10593-011-0699-ySearch in Google Scholar
[23] P. Molina, A. Arques, M. V. Vinader, J. Becher, K. Brondum, J. Org. Chem.1988, 53, 4654.10.1021/jo00255a003Search in Google Scholar
[24] A. Michaelis, A. Reese, Ann. Chem.1886, 233, 51.10.1002/jlac.18862330104Search in Google Scholar
[25] A. Mustafa, M. M. Sidky, S. M. A. D. Zayed, W. M. Abdo, Monatsh. Chem. 1967, 98, 310.10.1007/BF00899946Search in Google Scholar
[26] R. Shabana, A. A. El-Barbary, A. B. A. G. Ghattas, S. O. Lawesson, C. Roming, Sulfur Lett.1984, 2, 224.Search in Google Scholar
[27] L.-N. He, R.-Y. Chen, Chem. Commun. 1997, 3, 461.Search in Google Scholar
[28] M. Kimman, R. Norman, S. Jan, Asian Pac. J. Cancer Prev.2012, 13, 411.10.7314/APJCP.2012.13.2.411Search in Google Scholar
[29] Y. Angell, D. Chen, F. Brahimi, H. U. Saragovi, K. Burgess, J. Am. Chem. Soc.2008, 130, 556.10.1021/ja074717zSearch in Google Scholar
[30] J.-Y. Le Questel, M. Berthelot, C. Laurence, J. Phys. Org. Chem.2000, 13, 347.10.1002/1099-1395(200006)13:6<347::AID-POC251>3.0.CO;2-ESearch in Google Scholar
[31] O. Meth-Cohn, B. Narine, B. Tarnowski, J. Chem. Soc., Perkin Trans. 11981, 1520.10.1039/p19810001520Search in Google Scholar
[32] N. M. Ibrahim, H. A. A.Yosef, M. R. H. Mahran, J. Chem. Res.2009, 4, 220.10.3184/030823409X435900Search in Google Scholar
[33] F. Ramirez, N. B. Desai, N. Mckelvie, J. Am. Chem. Soc.1962, 84, 1312.10.1021/ja00866a056Search in Google Scholar
[34] X-ray Crystallography Laboratory, National Research Centre of Egypt (NRC), Dokki, Giza (Egypt). Available at: http://www.xrdlab-nrc-eg.org/ (accessed March 2016).Search in Google Scholar
[35] R. W. W. Hooft, Collect, Nonius KappaCCD Data Collection Software, Nonius BV, Delft (The Netherlands), 1998.Search in Google Scholar
[36] L. Palatinus, G. Chapuis, J. Appl. Crystallogr.2007, 40, 786.10.1107/S0021889807029238Search in Google Scholar
[37] P. W. Betteridge, J. R. Carruthers, R. I. Cooper, K. Prout, D. J. Watkin, J. Appl. Crystallogr.2003, 36, 1487.10.1107/S0021889803021800Search in Google Scholar
[38] R. I. Cooper, A. L. Thompson, D. J. Watkin, J. Appl. Crystallogr.2010, 43, 1100.10.1107/S0021889810025598Search in Google Scholar
[39] A. L. Spek, Acta Crystallogr.2009, D65, 148.10.1107/S090744490804362XSearch in Google Scholar
[40] L. J. Farrugia, J. Appl. Crystallogr.2012, 45, 849.10.1107/S0021889812029111Search in Google Scholar
[41] K. Brandenburg, Diamond, Crystal and Molecular Structure Visualization, Crystal Impact, H. Putz & K. Brandenburg GbR, Bonn (Germany) 2012. Available at: http://www.crystalimpact.com/diamond/ (accessed March 2016).Search in Google Scholar
[42] M. Youns, G. M. Fathy, J. Cell. Biochem.2013, 114, 2654.10.1002/jcb.24612Search in Google Scholar PubMed
[43] L. Pinto-Garcia, T. Efferth, A. Torres, J. D. Hoheisel, M. Youns, Planta Med.2010, 76, 1155.10.1055/s-0030-1249931Search in Google Scholar PubMed
[44] M. Youns, T. Efferth, J. Reichling, K. Fellenberg, A. Bauer, J. D. Hoheisel, Biochem. Pharmacol.2009, 78, 273.10.1016/j.bcp.2009.04.014Search in Google Scholar PubMed
©2016 by De Gruyter
Articles in the same Issue
- Frontmatter
- In this Issue
- Review
- Cerium intermetallics with TiNiSi-type structure
- Synthesis of novel pyrazole derivatives using organophosphorus, stibine, and arsine reagents and their antitumor activities
- A highly efficient CuI nanoparticles-catalyzed synthesis of tetrahydrochromenediones and dihydropyrano[c]chromenediones under grinding
- Supramolecular architecture based on high-lacunary sandwich-type building blocks: synthesis, characterization, and properties
- Preparation and conformation of 3,4-anhydro-1,2-O-isopropylidene-5-O-mesyl-β-d-tagatopyranose and methyl 4-chloro-4-deoxy-1,3,5-tri-O-mesyl-β-d-fructopyranoside
- Chromium(III) complexes with 1,2,4-diazaphospholide and 2,6-bis(N-1,2,4-diazaphosphol-1-yl) pyridine ligands: synthesis, X-ray structural characterization, EPR spectroscopy analysis, and magnetic susceptibility studies
- Synthesis and antimicrobial activity of some linear dipeptide pyridine and macrocyclic pentaazapyridine candidates
- Studies on the synthesis and properties of 1,1,1-trinitroprop-2-yl urea, carbamate and nitrocarbamate
- Gold nanocrystal arrays as electrocatalysts for the oxidation of methanol and ethanol
- Syntheses, single-crystal structures, vibrational spectra and DSC/TG analyses of orthorhombic and trigonal Ag[N(CN)2]
Articles in the same Issue
- Frontmatter
- In this Issue
- Review
- Cerium intermetallics with TiNiSi-type structure
- Synthesis of novel pyrazole derivatives using organophosphorus, stibine, and arsine reagents and their antitumor activities
- A highly efficient CuI nanoparticles-catalyzed synthesis of tetrahydrochromenediones and dihydropyrano[c]chromenediones under grinding
- Supramolecular architecture based on high-lacunary sandwich-type building blocks: synthesis, characterization, and properties
- Preparation and conformation of 3,4-anhydro-1,2-O-isopropylidene-5-O-mesyl-β-d-tagatopyranose and methyl 4-chloro-4-deoxy-1,3,5-tri-O-mesyl-β-d-fructopyranoside
- Chromium(III) complexes with 1,2,4-diazaphospholide and 2,6-bis(N-1,2,4-diazaphosphol-1-yl) pyridine ligands: synthesis, X-ray structural characterization, EPR spectroscopy analysis, and magnetic susceptibility studies
- Synthesis and antimicrobial activity of some linear dipeptide pyridine and macrocyclic pentaazapyridine candidates
- Studies on the synthesis and properties of 1,1,1-trinitroprop-2-yl urea, carbamate and nitrocarbamate
- Gold nanocrystal arrays as electrocatalysts for the oxidation of methanol and ethanol
- Syntheses, single-crystal structures, vibrational spectra and DSC/TG analyses of orthorhombic and trigonal Ag[N(CN)2]